AVXL
Anavex Life Sciences Corp. · Healthcare
3.08
4.05%(+0.12)
Close3.17
2.92%(+0.09)
After HoursLast Updated: — ET
52W L: $2.6152W H: $13.99
$3.10
CHG-1.43 (-31.57%)
H$4.90
L$2.61
VOL20M
AVXL (1h)
Anavex Life Sciences Corp. · Healthcare
NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present at the 25th Annual Needham Virtual Healthcare Conference, April 13 – 16, 2026. President and Chief Executive Officer Christopher U. Missling, PhD and his management team will present the Company scheduled at 1:30 PM (ET) on Tuesday, April 14th, 2026.
Dialogue continues with European Medicines Agency (EMA) to advance the development program of oral blarcamesine in early Alzheimer's disease
NEW YORK, March 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ: AVXL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
This decision follows feedback from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), which indicated it would not issue a positive opinion at this time.
NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it has withdrawn its application for the marketing authorization of blarcamesine in the EU as an add-on therapy for the treatment of early Alzheimer's disease in adults, which had been under review by the European Medicines Agency (EMA). The decision to withdraw the application follows feedback from the EMA's Committee for Medicinal Products for Human Use (CHMP) indicating that it would not be in a position to issue a positive opinion for the application at this time.
New data show brain-volume preservation correlates with patient outcomes Long-term clinical data indicate 77.4 weeks (17.8 months) time saved with oral blarcamesine compared to ADNI 1 control group after 144 weeks (33.1 months) of treatment Oral presentation at the AD/PD™ 2026 Conference Symposium: ‘Advances in AD treatment' highlights the convenience of oral blarcamesine for both patients and families NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced new data of blarcamesine was presented at the AD/PD™ 2026 Conference by Prof. Dr. Timo Grimmer, MD, and collaborators, titled, Advancing Alzheimer's Disease Care: Convenience for both Patients and Families with Oral Blarcamesine with Long-term Time Saved, drawing from the ANAVEX®2-73-AD-004 (NCT03790709) Phase IIb/III clinical program and its long-term open-label extension, ANAVEX®2-73-AD-EP-004 (NCT04314934).
MISSLING CHRISTOPHER U
director, officer: President and CEO
125,000 SH @ $8.58
2026-01-06
Boenisch Sandra
officer: PFO & Treasurer
12,500 SH @ $8.58
2026-01-06
Boenisch Sandra
officer: PFO & Treasurer
12,500 SH @ $5.36
2025-10-02
MISSLING CHRISTOPHER U
director, officer: President and CEO
125,000 SH @ $5.36
2025-10-02
MISSLING CHRISTOPHER U
director, officer: President and CEO
187,500 SH @ $5.04
2025-09-11
MISSLING CHRISTOPHER U
director, officer: President and CEO
145,048 SH @ $9.58
2025-09-11
MISSLING CHRISTOPHER U
director, officer: President and CEO
187,500 SH @ $5.04
2025-09-11
Boenisch Sandra
officer: PFO & Treasurer
12,500 SH @ $8.58
2025-08-20